This report highlights North America’s leadership in MASH therapeutics, focusing on advanced-stage (F4) fibrosis cases, emerging FGF21 and GLP‑1 therapies, and strategic competition among pharma players like Madrigal, Novo Nordisk, and Akero https://www.datamintelligence.com/research-report/north-america-metabolic-dysfunction-associated-steatohepatitis-treatment-market